LC8 Intrinsic Value Calculator – CALLIDITAS THERAPEUTICS AB Reports Positive FY2022 Q4 Earnings Results for Fourth Quarter
March 25, 2023
Earnings Overview
CALLIDITAS THERAPEUTICS AB ($BER:LC8) reported their FY2022 Q4 earnings results on December 31 2022, showing total revenue of SEK -3.7 million, a substantial 98.3% increase compared to the previous year. Net income in the fourth quarter was a remarkable SEK 429.0 million, a 1276.0% increase year-on-year.
Stock Price
On Thursday, CALLIDITAS THERAPEUTICS AB reported its positive financial results for the fourth quarter of FY2022. The stock opened at €8.8 and closed at €9.7 on Thursday, representing a 17.2% surge from its last closing price of €8.3. This marks a significant increase in CALLIDITAS THERAPEUTICS AB’s stock price and indicates that the company is in a strong financial position. The company’s quarterly performance was driven by strong sales of its innovative treatments for rare diseases, such as its proprietary drug Nefecon for treatment of IgA Nephropathy.
In addition, CALLIDITAS THERAPEUTICS AB has recently expanded into new markets, such as the United States, to further boost its revenue. Overall, CALLIDITAS THERAPEUTICS AB’s strong fourth quarter performance and strategic expansion into new markets have allowed the company to achieve positive earnings results. This result is a testament to the company’s commitment to developing innovative treatments and expanding its operations globally. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for LC8. More…
| Total Revenues | Net Income | Net Margin |
| 802.88 | -412.27 | -51.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for LC8. More…
| Operations | Investing | Financing |
| -311.35 | -5.14 | 575.99 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for LC8. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.95k | 1.19k | 14.28 |
Key Ratios Snapshot
Some of the financial key ratios for LC8 are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 63.2% | – | -52.6% |
| FCF Margin | ROE | ROA |
| -38.8% | -35.3% | -13.5% |
Analysis – LC8 Intrinsic Value Calculator
At GoodWhale, we have conducted a thorough analysis of CALLIDITAS THERAPEUTICS AB’s wellbeing and are pleased to present our findings. According to our proprietary Valuation Line, the fair value of CALLIDITAS THERAPEUTICS AB’s share is around €2181.2. However, the stock is currently traded at €9.7, meaning it is undervalued by 99.6%. We believe that this presents an excellent opportunity for investors to get involved in a potentially profitable venture. More…
Summary
CALLIDITAS THERAPEUTICS AB has seen a significant improvement in its financial performance in the fourth quarter of its fiscal year 2022, with total revenue of SEK -3.7 million, representing a 98.3% increase over the same period a year before. Net income for the quarter was SEK 429.0 million, an impressive 1276.0% increase year-over-year. This positive financial performance was reflected in a corresponding rise in stock price following the news. Investors can look forward to continued positive performance from CALLIDITAS THERAPEUTICS AB in the future as the company’s fundamentals appear to be strong and sustainable.
